Fingolimod, a modulator of S1PR1, S1PR3, S1PR4 subtypes, has been approved for the therapy of RRMS, whereas the more selective S1PR1 and S1PR5 modulator siponimod is an approved treatment for active SPMS. Here, S1PR5 is linked to relapsing-remitting multiple sclerosis.